<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739985</url>
  </required_header>
  <id_info>
    <org_study_id>P081228</org_study_id>
    <secondary_id>2009-017293-20</secondary_id>
    <nct_id>NCT01739985</nct_id>
  </id_info>
  <brief_title>Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis</brief_title>
  <acronym>VPOP2</acronym>
  <official_title>Postoperative Vomiting in Children: Evaluation of the Addition of Droperidol to Conventional Bi-prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefit of addition of droperidol to prophylaxis
      with ondansetron and dexamethasone in children with high risk of postoperative vomiting
      (POV). In adults some authors showed that the effectiveness of prophylaxis is correlated to
      the number of molecules or specific procedures used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall incidence of postoperative vomiting between 25 and 30% for the pediatric
      population, but it can reach a much higher incidence associated with certain types of
      surgery, about 80% in some studies like strabismus surgery for example. The identification of
      patients at high risk of POV is possible through the use of risk score. It is currently only
      one pediatric validated risk score, but the investigators conducted a multicenter study on
      this subject, whose results are being analyzed. This should allow us to identify children at
      high risk of POV. In this targeted population, the prophylaxis should allow a significant
      reduction in the incidence of POV. In children only one study tried to evaluate the
      association of ondansetron, dexamethasone and droperidol to prevent postoperative vomiting.
      However, different doses of the different molecules were combined, the extremely complicated
      design of this study and important methodological bias do not provide evidence about the
      superiority of the combination of three anti-emetics compared with two anti-emetics. Our
      present randomized, double-blind study is designed to compare the effectiveness of Droperidol
      in combination with a conventional bi-prophylaxis (dexamethasone/ondansetron) to the
      conventional bi-prophylaxis alone to decrease the occurrence of postoperative vomiting in
      children at high risk. The combination ondansetron and dexamethasone is frequently assessed
      as an association to prevent postoperative vomiting also in the adult population and in the
      pediatric population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative vomiting</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">322</enrollment>
  <condition>Postoperative Vomiting</condition>
  <arm_group>
    <arm_group_label>Dexamethasone + ondansetron + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone + ondansetron + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone + ondansetron + Droperidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexamethasone + ondansetron + Droperidol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone + ondansetron + Placebo</intervention_name>
    <description>Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery</description>
    <arm_group_label>Dexamethasone + ondansetron + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone + ondansetron + Droperidol</intervention_name>
    <description>Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1</description>
    <arm_group_label>Dexamethasone + ondansetron + Droperidol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children scheduled for surgery and with high risk of postoperative vomiting, i.e. with
             VPOP score up to 4

          -  Between 3 to 18 years

          -  Informed consent signed or the owner (s) of parental

          -  Children receiving a social security system

        Exclusion Criteria:

          -  Ambulatory surgery

          -  Preoperative corticosteroids

          -  Postoperative sedation

          -  Allergy known to droperidol, ondansetron or dexamethasone

          -  Known hypokaliemia

          -  Known hypomagnesemia

          -  Bradycardia (&lt;55 bpm)

          -  Congenital long QT syndrome

          -  Treatment that induce prolonged QT

          -  Pheochromocytoma

          -  Severe depressive syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles ORLIAGUET, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Necker Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gunter JB, McAuliffe JJ, Beckman EC, Wittkugel EP, Spaeth JP, Varughese AM. A factorial study of ondansetron, metoclopramide, and dexamethasone for emesis prophylaxis after adenotonsillectomy in children. Paediatr Anaesth. 2006 Nov;16(11):1153-65.</citation>
    <PMID>17040305</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004 Jun 10;350(24):2441-51.</citation>
    <PMID>15190136</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Children</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Droperidol</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Droperidol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

